number
differ
speci
virus
caus
upper
lower
respiratori
infect
transplant
recipi
similar
exist
pathogen
gener
transmiss
viral
pathogen
occur
spread
person
person
direct
close
contact
contamin
secret
may
involv
droplet
fomit
addit
influenza
viru
may
spread
small
particl
aerosol
accordingli
attent
good
hygien
practic
particular
hand
wash
part
infect
control
prevent
hospit
support
care
mainstay
treatment
specif
antivir
agent
avail
coronaviru
parainfluenza
specif
data
rsv
influenza
piv
transplant
popul
discuss
detail
rna
viru
caus
season
annual
epidem
worldwid
temper
climat
rsv
strike
fall
winter
earli
spring
year
age
virtual
children
experienc
primari
infect
recent
year
becom
clear
reinfect
occur
throughout
life
symptom
rsv
infect
tend
milder
older
children
adult
individu
may
serv
reservoir
transmiss
suscept
host
rsv
recogn
caus
sever
diseas
bone
marrow
transplant
bmt
likewis
recogn
caus
respiratori
diseas
pediatr
solidorgan
transplant
increasingli
recogn
adult
recipi
riskfactor
develop
lower
respiratori
tract
diseas
bmt
recipi
rsv
infect
includ
lymphocytopenia
neutropenia
mani
bmt
recipi
infect
rsv
develop
lower
respiratori
tract
diseas
lower
tract
diseas
present
mortal
rate
rang
report
risk
factor
sever
diseas
organ
transplant
includ
infect
children
year
age
underli
lung
diseas
earli
acquisit
rsv
transplant
augment
immunosuppress
associ
increas
sever
diseas
studi
definit
diagnosi
made
growth
rsv
cell
line
howev
viru
quit
labil
sensit
diminish
quickli
specimen
inocul
promptli
onto
cell
cultur
line
number
commerci
rapid
antigen
detect
kit
shell
vial
assay
avail
permit
diagnosi
made
quickli
increas
sensit
compar
cultur
children
howev
adult
includ
immunocompromis
patient
may
low
titer
viru
upper
respiratori
tract
sensit
antigen
detect
adult
lower
seen
children
polymeras
chain
reaction
assay
pcr
also
avail
laboratori
one
commerci
multiplex
assay
hexaplex
podess
inc
waukesha
wi
usa
approv
food
drug
administr
fda
nasal
wash
aspir
shown
superior
nasal
swab
specimen
diagnosi
rsv
bronchoalveolar
lavag
recommend
assess
adult
suspect
lower
respiratori
tract
diseas
review
diagnosi
rsv
provid
tabl
support
care
recommend
biii
role
specif
antivir
treatment
controversi
ribavirin
shown
vitro
activ
rsv
aerosol
form
drug
approv
treatment
lower
respiratori
tract
diseas
due
rsv
certain
atrisk
popul
despit
fda
approv
convinc
data
describ
clinic
efficaci
agent
lack
consensu
util
drug
treatment
rsv
diseas
current
exist
publish
data
treatment
rsv
diseas
solid
organ
transplant
recipi
limit
howev
experi
treatment
bmt
recipi
may
provid
guidanc
treatment
rsv
diseas
solid
organ
transplant
recipi
bmt
recipi
high
mortal
rate
rsv
pneumonia
even
use
aerosol
ribavirin
prompt
clinic
investig
addit
therapeut
option
patient
popul
noncontrol
studi
use
combin
ribavirin
ivig
higher
rsv
titer
rsvivig
respigam
perform
appear
demonstr
benefit
use
earli
symptom
develop
bmt
recipi
high
mortal
rate
patient
popul
would
lead
mani
recommend
earli
therapi
bii
combin
aerosol
ribavirin
rsv
ivig
palivizumab
synagi
medimmun
inc
gaithesburg
maryland
rsvspecif
monoclon
antibodi
appear
benefici
bmt
recipi
even
present
lower
respiratori
tract
diseas
base
experi
mani
expert
would
recommend
use
combin
aerosol
ribavirin
either
rsv
ivig
palivizumab
treatment
rsv
upper
respiratori
tract
lower
respiratori
tract
infect
bmt
recipi
bii
combin
experi
limit
publish
experi
treatment
rsv
diseas
solid
organ
transplant
recipi
provid
support
follow
recommend
tabl
aerosol
ribavirin
use
treatment
solid
organ
transplant
patient
lower
tract
diseas
report
seem
benefit
biii
howev
studi
report
retrospect
experi
base
upon
publish
experi
pediatr
organ
transplant
recipi
patient
without
risk
factor
sever
diseas
upper
respiratori
infect
unlik
benefit
aerosol
ribavirin
dii
patient
upper
respiratori
tract
diseas
presenc
risk
factor
organ
transplant
recipi
lower
respiratori
tract
diseas
use
aerosol
ribavirin
combin
rsv
ivig
pavilizumab
consid
biii
prophylaxi
rsvspecif
monoclon
antibodi
palivizumab
high
titer
rsvivig
shown
effect
specif
group
highrisk
infant
young
children
howev
studi
conduct
evalu
use
solid
organ
transplant
set
cost
weight
adjust
dose
product
adult
would
extrem
high
unexpect
increas
risk
death
children
cyanot
heart
diseas
receiv
rsv
ivig
show
inabl
gener
use
immunoprophylaxi
one
popul
anoth
without
studi
despit
expert
would
support
use
immunoprophylaxi
studi
necessari
defin
risk
factor
sever
diseas
adult
solidorgan
transplant
recipi
develop
sensit
rapid
diagnost
assay
use
adult
util
immunoproprophylaxi
recipi
transplant
also
requir
evalu
final
trial
also
need
confirm
util
aerosol
ribavirin
alon
combin
rsvivig
treatment
patient
risk
progress
present
lower
respiratori
tract
diseas
influenza
viru
orthomyxoviru
consid
one
import
communityacquir
virus
lead
substanti
morbid
mortal
worldwid
antigen
variabl
give
viru
surviv
advantag
allow
continu
virul
yearli
epidem
studi
examin
preval
influenza
viru
infect
prospect
organ
transplant
recipi
retrospect
studi
demonstr
potenti
substanti
diseas
pediatr
recipi
influenza
infect
review
influenza
viru
infect
adult
organ
transplant
document
variabl
level
sever
may
due
differ
level
immunosuppress
type
transplant
season
variat
influenza
virul
addit
differ
prevent
vaccin
polici
dispar
respons
rate
vaccin
patient
differ
age
differ
immunosuppress
regimen
undoubtedli
affect
diseas
sever
diagnosi
influenza
infect
proven
isol
viru
cultur
rapid
method
shell
vial
cultur
antigen
detect
detect
neuraminidas
activ
rel
sensit
specif
depend
specimen
patient
sourc
commerci
avail
rapid
test
use
officebas
diagnost
test
adequ
specimen
collect
time
sampl
also
play
import
role
identifi
pathogen
viral
cultur
perform
specimen
obtain
first
day
ill
maxim
yield
viral
load
may
decreas
rapidli
afterward
cultur
typic
turn
posit
within
day
rapid
diagnost
test
identif
influenza
b
antigen
commerci
avail
nasopharyng
aspir
specimen
consid
optim
use
throat
swab
nasopharyng
swab
tend
result
lower
level
sensit
review
diagnosi
influenza
provid
tabl
prompt
treatment
influenza
infect
amantadin
rimantadin
newer
neuraminidas
inhibitor
zanamivir
oseltamivir
effect
studi
healthi
adult
latter
two
drug
efficaci
influenza
b
earli
treatment
influenza
inhal
zanamivir
oral
oseltamivir
appear
reduc
likelihood
lower
respiratori
tract
complic
eg
bronchiol
pneumonia
none
drug
proven
efficaci
prevent
seriou
complic
influenza
retrospect
analysi
indic
earli
antivir
treatment
amantadin
rimantadin
reduc
likelihood
develop
pneumonia
patient
acut
leukemia
undergon
bmt
review
recommend
treatment
influenza
viru
infect
solid
organ
transplant
recipi
provid
tabl
despit
absenc
data
organ
transplant
recipi
transplant
physician
would
recommend
use
antivir
agent
treatment
organ
transplant
recipi
influenza
viru
infect
biii
mani
expert
would
consid
use
neuraminidas
inhibitor
either
alon
combin
anoth
drug
concern
acquisit
resist
associ
use
amantadin
rimantadin
may
exceed
rate
patient
final
ribavirin
also
vitro
activ
influenza
viru
anecdot
report
use
immunocompet
host
sever
influenza
infect
suggest
possibl
activ
accordingli
would
advoc
addit
aerosol
ribavirin
one
antivir
agent
transplant
patient
seriou
influenza
infect
ciii
use
influenza
vaccin
highrisk
individu
includ
transplant
recipi
month
age
strongli
recommend
bii
influenza
vaccin
also
administ
peopl
contact
highrisk
patient
health
care
worker
household
contact
biii
respons
influenza
vaccin
studi
number
transplant
set
vaccin
year
specif
influenza
strain
recipi
type
lead
variat
antibodi
respons
sever
conclus
made
first
transplant
recipi
strong
respons
vaccin
healthi
control
despit
patient
achiev
protect
hemagglutinationinhibit
serum
antibodi
titer
accordingli
yearli
vaccin
strongli
consid
aii
yearli
vaccin
likewis
recommend
health
care
worker
household
contact
chemoprophylaxi
antivir
agent
use
effect
atrisk
popul
receiv
vaccin
opportun
respond
recent
vaccin
time
influenza
alreadi
circul
commun
biii
howev
failur
amantadin
rimantadin
may
occur
basi
antivir
resist
commun
prophylact
therapeut
use
agent
high
diagnosi
parainfluenza
reli
viral
isol
shell
vial
assay
use
rapid
antigen
detect
use
fluoresc
antibodi
stain
techniqu
directli
specimen
cultur
cell
addit
rna
detect
techniqu
recent
becom
avail
prolong
viral
shed
occur
immunosuppress
host
overview
diagnosi
parainfluenza
viru
provid
tabl
specif
antivir
treatment
avail
piv
infect
ribavirin
vitro
activ
use
treat
lung
transplant
recipi
lower
tract
diseas
therapeut
option
current
avail
consider
given
use
aerosol
ribavirin
highrisk
patient
pivassoci
sever
lower
tract
diseas
ciii
tabl
howev
analysi
uncontrol
studi
aerosol
ribavirin
bmt
recipi
parainfluenza
viru
diseas
found
littl
evid
antivir
effect
clinic
benefit
similarli
earli
use
oral
ribavirin
littl
benefit
prevent
progress
asymptomat
mild
upper
respiratori
tract
symptom
lower
respiratori
tract
diseas
specif
prophylaxi
avail
piv
note
good
attent
infect
control
practic
necessari
prevent
nosocomi
transmiss
outsid
hospit
set
infect
control
method
challeng
educ
recipi
famili
risk
communityacquir
virus
method
spread
allow
avoid
exposur
studi
defin
potenti
therapeut
role
ribavirin
treatment
piv
diseas
necessari
addit
multicenteredstudi
aim
identifi
potenti
prophylact
benefit
polyclon
ivig
contain
antibodi
piv
respiratori
virus
would
also
benefit
